Rockville, MD – February 18, 2011 – Accelovance, a privately held clinical research organization
reported its sixth year of continued revenue growth after closing out a successful 2010. The year
included an award of two Phase III rescue studies; several contracts with biotech companies
initiating Phase I and Phase II clinical programs; and new relationships with government-funded
Sponsors. Accelovance also gained continued industry recognition for its best-in-class services
with a second, consecutive “BEST CRO” ViE Award.
“The past 12 months have been remarkable, with 30% top line growth over last year. We are
proud of the efficiencies our enhanced study management has to offer,” commented Steve
Trevisan, President and CEO of Accelovance. “Revenue growth and industry awards support our
ability to deliver clinical solutions through a flexible offering of a CRO, Clinical Sites, Patient
Recruitment and Clinical Call Center.” In 2010, the Washington Business Journal added
Accelovance to its annual list of 50 Washington-area Fastest Growing Companies.
New programs will capitalize on Accelovance’s integrated service approach; CRO, sites and
recruitment solutions within our core market of vaccines, immunology and primary care
conditions. The CRO division will continue to focus on the business needs of biotech and
small/mid pharma with expanded areas of expertise in oncology, cardiovascular and cell/gene
therapy. An increased interest in Accelovance’s Clinical Call Center to support retention,
compliance, recruitment efforts and observational studies for Large Pharma indicates additional
growth opportunities over the next 12-18 months.
“A flexible, innovative offering that can be utilized by Sponsors big and small alike gives
Accelovance a diverse client base that will support overall corporate growth,” commented
Trevisan. Accelovance also had a 15% increase in employees to support new programs and
expanded therapeutic expertise. Similar hiring activity is anticipated for 2011.
Headquartered in Rockville, Maryland, Accelovance is a privately held company that has
developed a unique operational approach for delivering quality, on time, and cost effective clinical
studies. The Company tailors its offering of a full CRO, Clinical Sites, Patient Recruitment, and
Call Center to present a clinical solution that meets Sponsors’ needs. Accelovance’s ownership
and operation of six (6) research-dedicated clinical sites provides operational insight to study
conduct and patient recruitment that other CROs never acquire. Additionally, Accelovance has a
wholly owned subsidiary providing regulatory consulting and CRO services in China. These
capabilities can assist clients with global development programs or product registration in China,
the fastest growing pharmaceutical market in the world.
For more information, visit the company’s website at http://www.accelovance.com